# Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU

> **NCT01859117** · PHASE1 · COMPLETED · sponsor: **Celularity Incorporated** · enrollment: 15 (actual)

## Conditions studied

- Peripheral Arterial Disease
- Diabetic Foot

## Interventions

- **BIOLOGICAL:** 3 x 10^6 cells
- **BIOLOGICAL:** 10 x 10^6 cells
- **BIOLOGICAL:** 30 x 10^6 cells
- **BIOLOGICAL:** 100 x 10^6 cells

## Key facts

- **NCT ID:** NCT01859117
- **Lead sponsor:** Celularity Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01859117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01859117, "Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01859117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*